News › Industry News, Patient Care

Belgium Bans Use of Ozempic for Weight Loss Until Summer

November 15, 2023
Summer sunscreen

Belgium has decided to temporarily ban the use of Novo Nordisk’s diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country’s Official Gazette on Tuesday.

Ozempic is approved to treat Type 2 diabetes but has increasingly been prescribed “off-label” to treat weight loss because it has the same active ingredient as Novo’s hugely popular – and scarce – anti-obesity drug Wegovy.

In Britain, doctors and prescribers, including private online pharmacies, have been ordered to stop prescribing Ozempic to people who don’t have type 2 diabetes as soon as possible.

They are also banned from starting new patients with type 2 diabetes on the medicine for as long as the shortage lasts.

Read more at Reuters >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Misinformation on Hyaluronic Acid (HA) Fillers Taking Over Your Practice? A New Fact-Based Campaign by Allergan Aesthetics Sets the Story Straight
    • Hydrafacial Introduces HydraScalp with Keravive
    • CorralData Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Private Equity Bridgepoint Group Acquires Obagi Medical
    • Growth99 Introduces Gia: An AI Front Desk Built to Convert New Patient Inquiries Across Every Channel